ArticleFrontiers in nutrition2026
Polysaccharides from
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Functional dyspepsia (FD) is a common gastrointestinal disorder characterized by symptoms such as epigastric pain, bloating, and nausea. Current treatments have limited efficacy and significant side effects. Objective: This study aimed to characterize the structural properties of Materials and methods: Neutral ERP-N and acidic ERP-A were isolated from Results: Structural Analysis: ERP-N (13,415 Da) and ERP-A (3,691 Da) exhibited distinct monosaccharide compositions and linkages. Therapeutic Effects: ERP improved FD symptoms, reduced inflammation, regulated gut microbiota, and activated the PI3K/Akt/cGMP-PKG pathway in rats. Immunomodulatory Activity: ERP-N promoted the secretion of nitric oxide (NO), TNF- Conclusion: ERP may alleviate FD in association with gut microbiota modulation and changes in the PI3K/Akt/cGMP-PKG-related pathway. ERP-N also exhibits immunomodulatory activity, supporting the traditional use of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.